플리언트 테라퓨틱스PLRX 주가

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Pliant Therapeutics, Inc. (PLRX) RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 11:30 AM EDTCompany ParticipantsBernard Coulie -...

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company f

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Keith Cummings, M.D., Pliant’s Chief Financial Officer, will participate in a fireside chat on Tuesday, May

[ARS] ARS — ARS

[DEFA14A] DEFA14A — DEFA14A

[DEF 14A] 주주총회 위임장 — DEF 14A

[8-K] 중대 사건 — 8-K

[4] 내부자 거래 — FORM 4